US regulatory status: approved. Molecular target: Tissue-type plasminogen activator.
- Target
- Tissue-type plasminogen activator
- Mechanism
- Tissue-type plasminogen activator exogenous protein
pharma · Ischemic Stroke · Spinal Cord Injury
Neuroscience Trials Australia
Neuroscience Trials Australia drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Parkville, AU HQ
14 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Parkville, AU
- Employees
- 14
- Programs
- 5
- Drugs
- 9
- Patents
- 0
Neuroscience Trials Australia pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Neuroscience Trials Australia drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Membrane staining aid in ophthalmic surgery.
- Mechanism
- Membrane staining aid in ophthalmic surgery
-
Development asset linked to Neuroscience Trials Australia in public FDA and regional records.
-
Development asset linked to Neuroscience Trials Australia in public FDA and regional records.
-
ranolazine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
Development asset linked to Neuroscience Trials Australia in public FDA and regional records.
-
tenecteplase
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Tissue-type plasminogen activator.
- Target
- Tissue-type plasminogen activator
- Mechanism
- Tissue-type plasminogen activator exogenous protein
-
Development asset linked to Neuroscience Trials Australia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Plasminogen.
- Target
- Plasminogen
- Mechanism
- Plasminogen inhibitor